Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.13 -1.0%	$8.36	$6.38 ▼ $17.30	$883.23M	1.4	1.24 million shs	1.46 million shs
PHVS Pharvaris	$16.53 -1.1%	$15.45	$11.51 ▼ $25.50	$874.29M	-2.85	73,934 shs	189,848 shs
QURE uniQure	$14.56 -2.3%	$12.53	$3.73 ▼ $19.18	$797.54M	0.1	1.90 million shs	1.71 million shs
SLDB Solid Biosciences	$3.20 -3.0%	$3.12	$2.41 ▼ $10.37	$248.05M	2.32	1.08 million shs	868,844 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.98%	0.00%	+2.70%	+15.42%	-41.44%
PHVS Pharvaris	-1.14%	+3.38%	-10.55%	+3.96%	-14.79%
QURE uniQure	-2.28%	-3.96%	-1.36%	+10.76%	+213.12%
SLDB Solid Biosciences	-3.03%	+13.88%	-3.32%	-42.75%	-57.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.2594 of 5 stars	3.5	1.0	3.5	1.7	0.6
PHVS Pharvaris	2.1432 of 5 stars	3.5	3.0	3.1	0.8	0.0
QURE uniQure	2.3263 of 5 stars	3.5	1.0	3.0	2.5	0.6
SLDB Solid Biosciences	3.9119 of 5 stars	4.6	1.0	2.9	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$19.43	112.80% Upside
PHVS Pharvaris	3.00	Buy	$40.67	146.02% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	159.74% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	365.63% Upside

Current Analyst Ratings Breakdown

Latest SLDB, AVDL, PHVS, and QURE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	QURE uniQure	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$194.45M	4.54	N/A	N/A	$0.98 per share	9.32
PHVS Pharvaris	N/A	N/A	N/A	N/A	$7.95 per share	N/A
QURE uniQure	$20.20M	39.48	N/A	N/A	$4.34 per share	3.35
SLDB Solid Biosciences	$8.09M	30.66	N/A	N/A	$6.27 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$0.27	N/A	152.17	N/A	-52.53%	-93.34%	-44.77%	8/14/2025 (Estimated)
PHVS Pharvaris	-$109.18M	-$3.01	N/A	N/A	N/A	N/A	-38.52%	-36.69%	8/13/2025 (Estimated)
QURE uniQure	-$308.48M	-$4.39	N/A	N/A	N/A	-837.80%	-188.82%	-32.17%	8/7/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)

Latest SLDB, AVDL, PHVS, and QURE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.97	2.60
PHVS Pharvaris	N/A	19.08	19.08
QURE uniQure	0.92	6.51	6.51
SLDB Solid Biosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
PHVS Pharvaris	N/A
QURE uniQure	78.83%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
PHVS Pharvaris	11.84%
QURE uniQure	4.74%
SLDB Solid Biosciences	13.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.74 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
QURE uniQure	500	54.78 million	46.43 million	Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable

SLDB, AVDL, PHVS, and QURE Headlines

Recent News About These Companies

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28 at 2:49 PM | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28 at 8:00 AM | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by Brokerages

May 28 at 1:31 AM | marketbeat.com

Research Analysts Set Expectations for SLDB FY2025 Earnings

May 27, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor Fitzgerald

May 24, 2025 | marketbeat.com

Chardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock Price

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for SLDB Issued By William Blair

May 21, 2025 | marketbeat.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

Dimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

May 18, 2025 | marketbeat.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

May 17, 2025 | marketbeat.com

Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 16, 2025 | finanznachrichten.de

Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday

May 16, 2025 | marketbeat.com

Solid Biosciences files for $400M mixed securities shelf offering

May 16, 2025 | msn.com

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by Brokerages

May 4, 2025 | marketbeat.com

Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%

May 3, 2025 | aaii.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting

May 1, 2025 | nasdaq.com

Solid Biosciences to Participate at The Citizens Life Sciences Conference

April 30, 2025 | globenewswire.com

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

April 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, AVDL, PHVS, and QURE Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.13 -0.09 (-0.98%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$9.08 -0.05 (-0.59%)

As of 05/30/2025 05:40 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Pharvaris NASDAQ:PHVS

$16.53 -0.19 (-1.14%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$16.52 -0.01 (-0.03%)

As of 05/30/2025 07:33 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

uniQure NASDAQ:QURE

$14.56 -0.34 (-2.28%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$14.46 -0.10 (-0.69%)

As of 05/30/2025 07:54 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Solid Biosciences NASDAQ:SLDB

$3.20 -0.10 (-3.03%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.20 -0.01 (-0.16%)

As of 05/30/2025 07:57 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time